The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Somnath Chatterjee
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Somnath Chatterjee, Promoter, Chairman & Joint Managing Director of Suraksha Diagnostic Ltd, acquired 8,235 equity shares through an open market purchase on 13 August 2025. His voting shareholding rose from 5.051% (26,30,530 shares) to 5.067% (26,38,765 shares), a marginal increase of 0.016%. The disclosure was filed under Regulation 29(2) of SEBI's Substantial Acquisition of Shares & Takeovers (SAST) Regulations, 2011, triggering reporting obligations as his holding sits at the 5% disclosure threshold. The transaction was executed on both BSE (scrip code 544293) and NSE (symbol SURAKSHA).
This is a very small, incremental open market purchase by the promoter, signalling modest confidence but unlikely to move the stock price meaningfully. It suggests creeping promoter accumulation just above the 5% reporting threshold rather than a major strategic stake change.